Lineage Cell Therapeutics Inc (AMEX: LCTX) is -44.50% lower on its value in year-to-date trading and has touched a low of $0.50 and a high of $1.61 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The LCTX stock was last observed hovering at around $0.57 in the last trading session, with the day’s gains setting it 0.04%.
Currently trading at $0.61, the stock is -25.30% and -29.12% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 8.64 million and changing 5.42% at the moment leaves the stock -39.80% off its SMA200. LCTX registered -37.53% loss for a year compared to 6-month loss of -34.95%. The firm has a 50-day simple moving average (SMA 50) of $0.86 and a 200-day simple moving average (SMA200) of $1.00755.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -31.25% gain in the last 1 month and extending the period to 3 months gives it a -29.67%, and is -33.02% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 18.66% over the week and 9.20% over the month.
Lineage Cell Therapeutics Inc (LCTX) has around 75 employees, a market worth around $114.24M and $8.72M in sales. Profit margin for the company is -230.66%. Distance from 52-week low is 21.00% and -62.42% from its 52-week high. The company has generated returns on investments over the last 12 months (-29.66%).
with sales reaching $1.66M over the same period.The EPS is expected to grow by 2.78% this year, but quarterly earnings will post -11.01% year-over-year. Quarterly sales are estimated to shrink -21.78% in year-over-year returns.
Lineage Cell Therapeutics Inc (LCTX) Top Institutional Holders
143.0 institutions hold shares in Lineage Cell Therapeutics Inc (LCTX), with institutional investors hold 50.79% of the company’s shares. The shares outstanding are 188.84M, and float is at 187.66M with Short Float at 8.49%. Institutions hold 50.56% of the Float.
The top institutional shareholder in the company is BROADWOOD CAPITAL INC with over 41.67 million shares valued at $41.55 million. The investor’s holdings represent 22.7798% of the LCTX Shares outstanding. As of 2024-06-30, the second largest holder is BLACKROCK INC. with 9.56 million shares valued at $9.53 million to account for 5.2264 of the shares outstanding. The other top investors are VANGUARD GROUP INC which holds 8.47 million shares representing 4.6329% and valued at over $8.45 million, while DEFENDER CAPITAL, LLC. holds 2.7188 of the shares totaling 4.97 million with a market value of $4.96 million.
Lineage Cell Therapeutics Inc (LCTX) Insider Activity
The most recent transaction is an insider purchase by Howe Jill Ann, the company’s Chief Financial Officer. SEC filings show that Howe Jill Ann bought 15,000 shares of the company’s common stock on Nov 26 ’24 at a price of $0.59 per share for a total of $8850.0. Following the purchase, the insider now owns 25500.0 shares.
Lineage Cell Therapeutics Inc disclosed in a document filed with the SEC on Nov 26 ’24 that Samuel George A. III (General Counsel) bought a total of 15,000 shares of the company’s common stock. The trade occurred on Nov 26 ’24 and was made at $0.60 per share for $9000.0. Following the transaction, the insider now directly holds 22184.0 shares of the LCTX stock.
Still, SEC filings show that on Nov 22 ’24, Mulroy Michael H. (Director) acquired 40,000 shares at an average price of $0.57 for $22640.0. The insider now directly holds 298,555 shares of Lineage Cell Therapeutics Inc (LCTX).
